Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, announced the approval of Helsinn Pharmaceuticals, Shanghai branch, by the Shanghai Administration for Industry and Commerce with a 30-year term
The establishment of the new office in Shanghai reflects Helsinn’s long-term commitment to China and provides Helsinn with a platform to pursue commercial activities.
Helsinn plans to provide innovative and high-quality products to improve the lives of people with cancer, in line with its core values of quality, integrity and respect.
With the establishment of Helsinn Pharmaceuticals and after the anticipated approval of the first products next year, Helsinn will continue to expand its presence in China, via a commercial arm focused on Shanghai, as well as seeking to establish pan-China collaborations with partners to prepare for the launch of future products.
For many years, Helsinn has forged a strong presence in China, via its clinical and regulatory activities, licensing and commercial collaborations, on several of Helsinn's supportive care products.
Currently, several of these products are under registration with The China Food and Drug Administration (CFDA) with an estimated time for approval within 2018.
With this continued momentum, Helsinn aims to steadily grow and become a leading player in cancer care in China.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, said: “Helsinn has been developing a presence in China for the past five years and we have developed valuable experience, learnings and network. With the opening of our Shanghai office we will now be more visible and have the opportunity to capitalise on the groundwork we have already put in.”
“China is a large, diverse and dynamic market and we are delighted to have a permanent presence here as we expand our global footprint and seek to build out new avenues to help more people with cancer around the world.”